Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Theriva Biologics, Inc. (TOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-11-12
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 420.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2014 was 2.38M shares, a 970.79% increase from fiscal 2013.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2013 was 222.50K shares, a 89.28% decline from fiscal 2012.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2012 was 2.08M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | |||||
| 2024-09-30 | 420.00 shares 10-Q · filed 2024-11-12 | 420.00 shares derived: sum of 2 quarters · filed 2025-08-11 | 0.00 shares 10-Q · filed 2025-11-12 | 420.00 shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 0.00 shares 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | |||||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-12 | 0.00 shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-08 | 0.00 shares 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-07 | |||||
| 2022-09-30 | 3.00K shares 10-Q · filed 2023-11-13 | 3.00K shares derived: sum of 2 quarters · filed 2023-11-13 | 3.00K shares 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 0.00 shares 10-Q · filed 2023-08-08 | 0.00 shares 10-Q · filed 2023-08-08 | 3.00K shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | |||||
| 2014-12-31 | 2.38M shares 10-K · filed 2015-03-16 | |||||
| 2013-12-31 | 222.50K shares 10-K · filed 2015-03-16 | |||||
| 2012-12-31 | 2.08M shares 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |